Hubbard on assignment at FDA
This article was originally published in The Tan Sheet
Executive Summary
Former FDA associate commissioner Bill Hubbard, an oft-quoted critic of the agency, leaves his advising position at the advocacy group Alliance for a Stronger FDA to return to FDA temporarily. In a May 27 e-mail, Hubbard said he is working in the Office of the Commissioner to help the new leadership in "getting things going." As for the regulatory areas or issues he is addressing, Hubbard said his duties are not limited
You may also be interested in...
Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
Biotin And ‘Healthy Hair’: Federal Pre-emption Clips False Advertising Complaint In California
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: